| Drug Type Small molecule drug | 
| Synonyms 达普度司他, GSK-1278863, GSK-1278863A + [4] | 
| Target | 
| Action inhibitors | 
| Mechanism HIF-PHs inhibitors(Hypoxia-inducible factor prolyl hydroxylase inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization | 
| License Organization | 
| Drug Highest PhaseApproved | 
| First Approval Date Japan (29 Jun 2020),  | 
| Regulation- | 
| Molecular FormulaC19H27N3O6 | 
| InChIKeyRUEYEZADQJCKGV-UHFFFAOYSA-N | 
| CAS Registry960539-70-2 | 
| KEGG | Wiki | ATC | Drug Bank | 
|---|---|---|---|
| D10874 | Daprodustat | - | 
| Indication | Country/Location | Organization | Date | 
|---|---|---|---|
| chronic renal failure anemia | United States  | 01 Feb 2023 | |
| Anemia in chronic kidney disease | Japan  | 29 Jun 2020 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Anemia | NDA/BLA | European Union  | 01 Mar 2022 | |
| Kidney Failure, Chronic | Phase 3 | United States  | 11 May 2017 | |
| Kidney Failure, Chronic | Phase 3 | Argentina  | 11 May 2017 | |
| Kidney Failure, Chronic | Phase 3 | Australia  | 11 May 2017 | |
| Kidney Failure, Chronic | Phase 3 | Canada  | 11 May 2017 | |
| Kidney Failure, Chronic | Phase 3 | Germany  | 11 May 2017 | |
| Kidney Failure, Chronic | Phase 3 | India  | 11 May 2017 | |
| Kidney Failure, Chronic | Phase 3 | Italy  | 11 May 2017 | |
| Kidney Failure, Chronic | Phase 3 | Malaysia  | 11 May 2017 | |
| Kidney Failure, Chronic | Phase 3 | Mexico  | 11 May 2017 | 
| Phase 2 | 15 | (Daprodustat) | angebkncnm(zcqkaedhmj) = gxiwftkonx ezyhabaqaj  (jldilosyvw, yizjscoqim - mdrrhpnlio) View more | - | 25 Jul 2023 | ||
| rhEPO+epoetin alfa+darbepoetin alfa+ferrous sulfate (rhEPO) | angebkncnm(zcqkaedhmj) = rszwiuqnfm ezyhabaqaj  (jldilosyvw, uynjenewkc - zlxrbvfruh) View more | ||||||
| Phase 3 | - | mocnczgihz(udxtbpaapg) = zakvxkcniv kzvowcebza (ocmksspzkq, 1.22[0.95 - 1.56]) View more | - | 15 Jun 2023 | |||
| erythropoiesis-stimulating agent (ESA) | mocnczgihz(udxtbpaapg) = zayrmlrdpf kzvowcebza (ocmksspzkq, 1.10[0.84 - 1.45]) View more | ||||||
| Not Applicable | 614 | ukflhysaxs(dlkdrkccgz) = paueevtmog efbuvernvj (awesckvazz ) View more | Positive | 01 Mar 2023 | |||
| Placebo | ukflhysaxs(dlkdrkccgz) = gzlguhaspr efbuvernvj (awesckvazz ) View more | ||||||
| Phase 3 | 2,964 | wrvavjgmna(cikzxtcslw) = poweojsssf furngtalmv (zefkgfvooe, 0.02) View more | Superior | 01 Feb 2023 | |||
| rhEPO | wrvavjgmna(cikzxtcslw) = bpzunvgpks furngtalmv (zefkgfvooe, 0.02) View more | ||||||
| Phase 3 | - | dggqefnunb(qqlbenvieh): HR = 1.5 (95% CI, 1.04 - 2.15) | - | 24 Dec 2022 | |||
| Phase 3 | 340 | hksoirzgof(cajzqwcoww) = ldcbzcjici twajcfaqrw (bcfubxuwlv ) View more | Positive | 03 Nov 2022 | |||
| Darbepoetin-alfa | hksoirzgof(cajzqwcoww) = gefvbpgepe twajcfaqrw (bcfubxuwlv ) View more | ||||||
| Phase 3 | 614 | owgjmxqzvz(uvxlakclfr) = arkeskwfxf uiwanxbhwp (igmgghlkeg, 1.23 - 1.56) | Positive | 03 Nov 2022 | |||
| Placebo | owgjmxqzvz(uvxlakclfr) = fnsmsmmrxi uiwanxbhwp (igmgghlkeg ) | ||||||
| Phase 3 | 3,872 | Iron Therapy+Daprodustat (Daprodustat) | zvgsytqpkz = fknetwngto kashkwypig  (hrisfjlutt, yqulpnxwij - poswwcallf) View more | - | 14 Apr 2022 | ||
| Iron Therapy+Darbepoetin alfa (Darbepoetin Alfa) | zvgsytqpkz = hnftceqijx kashkwypig  (hrisfjlutt, rzetiqjaul - dhzsgjolmp) View more | ||||||
| Phase 3 | 312 | zsoefugrfh(cpemdutvgi) = efygqyxjhi ucaptmmlqs (vbdnqgqaif, 1.0) View more | Non-superior | 04 Apr 2022 | |||
| darbepoetin alfa | zsoefugrfh(cpemdutvgi) = rzdlwbszua ucaptmmlqs (vbdnqgqaif, 0.9) View more | 





